MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Merck & Co Inc.

Suletud

SektorTervishoid

87.05 -2.91

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

86.61

Max

89.64

Põhinäitajad

By Trading Economics

Sissetulek

583M

3.7B

Müük

-1B

16B

P/E

Sektori keskmine

13.696

73.239

Aktsiakasum

1.72

Dividenditootlus

3.51

Kasumimarginaal

23.963

Töötajad

73,000

EBITDA

1.3B

6.9B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+24.41% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.51%

3.06%

Järgmine tulemuste avaldamine

24. apr 2025

Järgmine dividendimakse kuupäev

7. apr 2025

Järgmine aktsia dividendi kuupäev (ex-date)

16. juuni 2025

Turustatistika

By TradingEconomics

Turukapital

-19B

233B

Eelmine avamishind

89.96

Eelmine sulgemishind

87.05

Uudiste sentiment

By Acuity

37%

63%

123 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Merck & Co Inc. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. veebr 2025, 12:33 UTC

Tulu

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4. veebr 2025, 11:57 UTC

Tulu

Merck 4Q Sales Increase Results in Swing to Profit

24. märts 2025, 05:00 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5. märts 2025, 19:42 UTC

Peamised uudised

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5. märts 2025, 10:30 UTC

Peamised uudised

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5. veebr 2025, 12:00 UTC

Peamised uudised

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4. veebr 2025, 14:48 UTC

Tulu

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

4. veebr 2025, 11:51 UTC

Tulu

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

4. veebr 2025, 11:50 UTC

Tulu

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

4. veebr 2025, 11:31 UTC

Tulu

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

4. veebr 2025, 11:31 UTC

Tulu

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

4. veebr 2025, 11:31 UTC

Tulu

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

4. veebr 2025, 11:31 UTC

Tulu

Merck 4Q Januvia/Janumet Sales $487M >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck 4Q Keytruda Sales Up 19% >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck 4Q Keytruda Sales $7.84B >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck 4Q Pharmaceutical Sales Up 7% >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck 4Q Pharmaceutical Sales $14.04B >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck Sees FY Adj EPS $8.88-Adj EPS $9.03 >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck: Anticipate Strong Growth in Back Half of 2025, as Well as in Both 2026 and 2027 >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck Sees FY Rev $64.1B-$65.6B >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck: Believe Temporary Pause Will Facilitate a More Rapid Reduction of Excess Inventory >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck: Expect Strength in Oncology and Contributions From Ongoing and New Launches of Important Products in Both Human and Animal Health Businesses to More Than Offset GARDASIL Headwind >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck 4Q Adj EPS $1.72 >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck: Gardasil Market Dynamics in China Do Not in Any Way Diminish the Confidence Co. Has in the Business >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck 4Q Net $3.74B >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck: Excluding Sales of Gardasil in China in Both 2024 and 2025, Expect Strong 2025 Growth Between 7%-9% (Ex-FX) Driven by Continued Strength in Oncology and Animal Health as Well as Contributions From New Product Launches >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck: Sales Outlook Reflects Reassessment of Market for Gardasil/Gardasil 9 in China and Decision to Temporarily Pause Shipments Until at Least Mid-Year >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck Sees FY25 Sales $64.1B-$65.6B >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck: Decline in 4Q Januvia/Janumet Sales Primarily Due to Lower Pricing in U.S., and Ongoing Generic Competition in Many International Markets and Supply Constraints in China >MRK

4. veebr 2025, 11:30 UTC

Tulu

Merck 4Q Winrevair Sales $200M >MRK

Võrdlus sarnastega

Hinnamuutus

Merck & Co Inc. Prognoos

Hinnasiht

By TipRanks

24.41% tõus

12 kuu keskmine prognoos

Keskmine 111.67 USD  24.41%

Kõrge 138 USD

Madal 95 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Merck & Co Inc. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

17 ratings

11

Osta

6

Hoia

0

Müü

Tehniline skoor

By Trading Central

89.32 / 93.08Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

123 / 386 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.